先看重點
在1182名血壓控制不佳的英國成年人中,使用家庭自測血壓來指導調藥,12個月時收縮壓與常規診療相比的差值為-3.5 mm Hg(95%置信區間-5.8至-1.2),加上遠端監測則為-4.7 mm Hg(95%置信區間-7.0至-2.4)。試驗為非盲設計,主要分析缺失15%的參與者,資助方之一是血壓計廠商。
證據類型
隨機對照試驗
解讀依據
公開摘要
閱讀重點
對照與不確定性
研究在問什麼
以往關於用自測血壓來調整降壓藥的試驗結果相互矛盾,遠端監測相比單純自測是否有額外價值也不清楚。TASMINH4試驗想檢驗在基層醫療中,自測血壓聯合或不聯合遠端監測用於調藥,與常規診療相比效果如何。
研究對象與方法
在英國142家全科診所進行的平行、非盲隨機對照試驗。納入年齡大於35歲、血壓高於140/90 mm Hg且願意自測血壓的成年人,透過安全的網路系統按1:1:1隨機分入自測血壓組(n=395)、自測加遠端監測組(n=393)或以診室血壓為依據的常規診療組(n=394)。主要結局為12個月時診室測量的收縮壓。主要分析採用可獲得的病例(1003人,85%),敏感性分析使用多重插補。
主要發現
以下為作者報告的結果。數值須連同族群和不確定性一起閱讀。
- 112個月時,自測組平均收縮壓為137.0 mm Hg(SD 16.7),遠端監測組為136.0 mm Hg(SD 16.1),常規診療組為140.4 mm Hg(SD 16.5)。
- 2與常規診療相比,校正後的平均差值在單純自測組為-3.5 mm Hg(95%置信區間-5.8至-1.2),在遠端監測組為-4.7 mm Hg(95%置信區間-7.0至-2.4)。
- 3自測組與遠端監測組之間差異不顯著(校正後平均差值-1.2 mm Hg,95%置信區間-3.5至1.2)。
- 4使用多重插補的敏感性分析結果相似,三組不良事件相近。
限制與不確定性
- 1參與者和研究者均未設盲,這可能影響血壓管理和結果記錄。
- 21182名參與者中只有1003人(85%)納入主要分析,約15%沒有12個月時的結果。
- 3參與者需願意自測血壓,因此結果未必適用於不願意自測的人。
- 4資助方包括家用血壓計廠商Omron Healthcare UK,本解讀僅基於摘要。
日常健康啟示
由醫師根據家庭血壓讀數調整藥物,比僅依靠診室讀數多帶來了幅度不大但確實存在的降壓效果,而且透過遠端監測傳送讀數並不明顯優於在診所檢視。不要根據家庭讀數自行改藥;這裡的獲益來自醫師據此行動,請與醫師商量自測血壓的做法。
如何連結自己的資料
合適的工具是經過驗證的上臂式家用血壓計:在固定時間、坐姿休息後測量,記錄讀數並提供平均值,而不是單次數值。能估測血壓的腕戴手錶不在本試驗的測試範圍內。
如何理解這類證據
隨機分組有助於因果推斷,仍須檢查分配、盲法、失去追蹤、追蹤時間和具體對照;標為隨機試驗不自動意味著高確定性。
作者的結構化摘要 English
以下英文摘要依所記錄的開放授權轉載,屬於作者原始材料,並非 MoveVitals 解讀。上方已提供研究解讀,分別說明作者結果與本站解釋;重要結論可直接查核原文。
Background
Studies evaluating titration of antihypertensive medication using self-monitoring give contradictory findings and the precise place of telemonitoring over self-monitoring alone is unclear. The TASMINH4 trial aimed to assess the efficacy of self-monitored blood pressure, with or without telemonitoring, for antihypertensive titration in primary care, compared with usual care.
Methods
This study was a parallel randomised controlled trial done in 142 general practices in the UK, and included hypertensive patients older than 35 years, with blood pressure higher than 140/90 mm Hg, who were willing to self-monitor their blood pressure. Patients were randomly assigned (1:1:1) to self-monitoring blood pressure (self-montoring group), to self-monitoring blood pressure with telemonitoring (telemonitoring group), or to usual care (clinic blood pressure; usual care group). Randomisation was by a secure web-based system. Neither participants nor investigators were masked to group assignment. The primary outcome was clinic measured systolic blood pressure at 12 months from randomisation. Primary analysis was of available cases. The trial is registered with ISRCTN, number ISRCTN 83571366.
Findings
1182 participants were randomly assigned to the self-monitoring group (n=395), the telemonitoring group (n=393), or the usual care group (n=394), of whom 1003 (85%) were included in the primary analysis. After 12 months, systolic blood pressure was lower in both intervention groups compared with usual care (self-monitoring, 137·0 [SD 16·7] mm Hg and telemonitoring, 136·0 [16·1] mm Hg vs usual care, 140·4 [16·5]; adjusted mean differences vs usual care: self-monitoring alone, -3·5 mm Hg [95% CI -5·8 to -1·2]; telemonitoring, -4·7 mm Hg [-7·0 to -2·4]). No difference between the self-monitoring and telemonitoring groups was recorded (adjusted mean difference -1·2 mm Hg [95% CI -3·5 to 1·2]). Results were similar in sensitivity analyses including multiple imputation. Adverse events were similar between all three groups.
Interpretation
Self-monitoring, with or without telemonitoring, when used by general practitioners to titrate antihypertensive medication in individuals with poorly controlled blood pressure, leads to significantly lower blood pressure than titration guided by clinic readings. With most general practitioners and many patients using self-monitoring, it could become the cornerstone of hypertension management in primary care.
Funding
National Institute for Health Research via Programme Grant for Applied Health Research (RP-PG-1209-10051), Professorship to RJM (NIHR-RP-R2-12-015), Oxford Collaboration for Leadership in Applied Health Research and Care, and Omron Healthcare UK.
來源與署名
Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial.
McManus RJ, Mant J, Franssen M, Nickless A, Schwartz C, Hodgkinson J, Bradburn P, Farmer A, Grant S, Greenfield SM, Heneghan C, Jowett S, Martin U, Milner S, Monahan M, Mort S, Ogburn E, Perera-Salazar R, Shah SA, Yu LM, Tarassenko L, Hobbs FDR, TASMINH4 investigators.
Lancet (London, England) · 2018-02-27
DOI: 10.1016/s0140-6736(18)30309-x ↗PubMed · 29499873 ↗Europe PMC · 所記錄的開放授權: cc by ↗摘要著作權歸原作者,依來源紀錄的開放授權轉載。中文譯文協助閱讀,英文摘要供查核術語及具體數值;本站的方法學解釋與作者結論分別呈現。
MoveVitals 編輯解讀 · 健康教育內容 · 未記錄個人臨床審閱
來源查核日期 2026-11-01
實用健康指南
放在一起讀
晝夜活動節律紊亂與更高的死亡風險相關(109,365人)
在7項觀察性研究、共109,365名參與者中,晝夜活動對比較弱(相對振幅較低)與更高的心血管死亡風險(風險比[HR]1.50,95%置信區間1.13至1.98)和全因死亡風險(HR 1.46,95%置信區間1.27至1.68)相關。證據基礎小,又是觀察性的,不能說明改善節律就能降低風險,疾病本身也可能擾亂節律。
Journal of the American Heart Association
五類運動都降低了靜息血壓,等長訓練降幅最大
彙總270項隨機試驗、共15,827名參與者的結果,有氧、抗阻、聯合、間歇和等長訓練與無介入對照組相比都降低了靜息血壓(各P<0.001),其中等長訓練降幅最大:收縮壓下降8.24 mm Hg,舒張壓下降4.00 mm Hg。各方式之間的排序部分來自間接比較,各試驗也不盡相同,所以排序不是個人的運動處方。
British Journal of Sports Medicine
鹽替代品使中國農村高危族群的中風、主要心血管事件和死亡率下降
在中國農村600個村莊、20,995名有中風史或年齡在60歲及以上且有高血壓的人中,使用鹽替代品(氯化鈉75%、氯化鉀25%)的中風發生率低於普通鹽:平均追蹤4.74年,每1000人年29.14次對33.65次(率比0.86,95%置信區間0.77至0.96;P=0.006)。死亡也更低(率比0.88),嚴重高鉀血癥事件沒有顯著增多,但試驗為開放標籤設計,且在中國農村開展。
The New England Journal of Medicine
智慧手錶脈搏不規則提醒較少見,做貼片檢查者34%確有房顫
在419,297名沒有已知心房顫動(房顫)的蘋果手錶使用者中,0.52%收到脈搏不規則提醒;返還可用心電貼片的450人中,34%確認有房顫(97.5%置信區間29至39)。提醒發出時恰有貼片記錄的,通知的陽性預測值為0.84(95%置信區間0.76至0.92),但收到提醒者中僅20.8%返還了貼片,沒有收到提醒的人未被監測,所以手錶沒有提醒並不能排除房顫。
The New England Journal of Medicine

